Abstract:The interaction between SARS-CoV-2 Spike protein and angiotensin-converting enzyme 2 (ACE2) is essential to viral attachment and the subsequent fusion process. Interfering with this event represents an attractive avenue for the development of therapeutics and vaccine development. Here, a hybrid approach of ligand- and structure-based virtual screening techniques were employed to disclose similar analogues of a reported antiviral phytochemical, glycyrrhizin, targeting the blockade of ACE2 interaction with the SARS-CoV-2 Spike. A ligand-based similarity search using a stringent cut-off revealed 40 FDA-approved compounds in DrugBank. These filtered hits were screened against ACE2 using a blind docking approach to determine the natural binding tendency of the compounds with ACE2. Three compounds, deslanoside, digitoxin, and digoxin, were reported to show strong binding with ACE2. These compounds bind at the H1-H2 binding pocket, in a manner similar to that of glycyrrhizin which was used as a control. To achieve consistency in the docking results, docking calculations were performed via two sets of docking software that predicted binding energy as ACE2-Deslanoside (AutoDock, −10.3 kcal/mol and DockThor, −9.53 kcal/mol), ACE2-Digitoxin (AutoDock, −10.6 kcal/mol and DockThor, −8.84 kcal/mol), and ACE2-Digoxin (AutoDock, −10.6 kcal/mol and DockThor, −8.81 kcal/mol). The docking results were validated by running molecular simulations in aqueous solution that demonstrated the stability of ACE2 with no major conformational changes in the ligand original binding mode (~ 2 Å average RMSD). Binding interactions remained quite stable with an increased potential for getting stronger as the simulation proceeded. MMGB/PBSA binding free energies were also estimated and these supported the high stability of the complexes compared to the control (~ −50 kcal/mol net MMGB/PBSA binding energy versus ~ −30 kcal/mol). Collectively, the data demonstrated that the compounds shortlisted in this study might be subjected to experimental evaluation to uncover their real blockade capacity of SARS-CoV-2 host ACE2 receptor.

Identification of Potential Antiviral Disaccharide Leading Compounds against SARS‐CoV‐2 through A Computer Aided Study

A Search for Medications to Treat COVID-19 Via in Silico Molecular Docking Models of the SARS-CoV-2 Spike Glycoprotein and 3CL Protease

Targeting the receptor binding domain and heparan sulfate binding for antiviral drug development against SARS-CoV-2 variants

Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening

Structure-Based Virtual Screening and Identification of Potential Inhibitors of SARS-CoV-2 S-RBD and ACE2 Interaction

Promising Terpenes As SARS-CoV-2 Spike Receptor-Binding Domain (RBD) Attachment Inhibitors to the Human ACE2 Receptor: Integrated Computational Approach

Identification of potential antiviral compounds against SARS-CoV-2 structural and non structural protein targets: A pharmacoinformatics study of the CAS COVID-19 dataset

Discovery of Novel Spike Inhibitors against SARS-CoV-2 Infection

Bionics Design of Affinity Peptide Inhibitors for SARS-CoV-2 RBD to Block SARS-CoV-2 RBD-ACE2 Interactions

Computational Analysis on the ACE2-derived Peptides for Neutralizing the ACE2 Binding to the Spike Protein of SARS-CoV-2

Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development

Docking heparan sulfate-based ligands as a promising inhibitor for SARS-CoV-2

Interactive Mechanism of Potential Inhibitors with Glycosyl for SARS-CoV-2 by Molecular Dynamics Simulation

Structure-based virtual screening and molecular docking of drugs against the SARS-CoV-2 spike protein-ACE2 receptor complex

Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2

Anin-silicoapproach to Identify the Potential Hot Spots in SARS-CoV-2 Spike RBD to Block the Interaction with ACE2 Receptor

Identification and characterization of 7-azaindole derivatives as inhibitors of the SARS-CoV-2 spike-hACE2 protein interaction

Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein

Ultra-Large-Scale Screening of Natural Compounds and Free Energy Calculations Revealed Potential Inhibitors for the Receptor-Binding Domain (RBD) of SARS-CoV-2

The Study of Antiviral Drugs Targeting SARS-CoV-2 Nucleocapsid and Spike Proteins Through Large-Scale Compound Repurposing.

Systematic virtual screening in search of SARS CoV-2 inhibitors against spike glycoprotein: pharmacophore screening, molecular docking, ADMET analysis and MD simulations